UK markets closed
NIKKEI 225
38,570.76 +88.65 (+0.23%) HANG SENG
18,430.39 +514.84 (+2.87%) CRUDE OIL
81.47 -0.10 (-0.12%) GOLD FUTURES
2,342.70 -4.20 (-0.18%) DOW
38,834.86 +56.76 (+0.15%) Bitcoin GBP
50,991.42 +226.45 (+0.45%)
NKTX Nov 2024 20.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:18AM EDT. Market open.
Loading interactive chart…
- GlobeNewswire
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
Senior R&D leader brings extensive expertise in immunology, clinical development and translational scienceSOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today announced that translational immunology expert George Vratsanos, M.D., FACR, is joining its board of directors. Dr. Vratsanos currently serves as Chief Medical Officer and Head of R&D for Jnana Th
- Simply Wall St.
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GuruFocus.com
Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis
Insights into Nkarta's Financial Health and Strategic Developments in Cell Therapy
© 2024 Yahoo. All rights reserved.